Haemonetics : JP Morgan 41st Annual Healthcare Conference Presentation

Haemonetics Corporation

JP Morgan 41st Annual Healthcare Conference

January 10, 2023

© 2023 Haemonetics Corporation

Important Information

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation (the "Company"), including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company's products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the impact of the COVID-19 pandemic on the Company's operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company's most recent Annual Report on Form 10-K under the headings "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" and in the Company's other periodic filings with the U.S. Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements..

Non-GAAP Financial Measures

This presentation includes estimates of future financial performance that are based on non-GAAP financial measures as defined under applicable SEC rules and regulations. Non-GAAP

financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. We strongly

encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. Descriptions of non-GAAP measures referenced in this presentation are available on our website at www.haemonetics.com. The Company does not provide a reconciliation of forward-lookingnon-GAAP measures referenced in this presentation because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts. Estimates of future financial performance in this presentation represent the Company's long-term goals and are not intended as guidance. See "Safe Harbor for Forward-Looking Statements" above regarding forward-looking statements made in this presentation.

Not a Recommendation of any Security

This presentation provides an overview of the Company and is not intended to be taken by, and should not be taken by, any individual recipient as a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.

2

Haemonetics - Key Accomplishments Since IR Day

Fueling recovery in plasma collection volumes

Accomplishing key growth and competitive milestones across our businesses

Driving expansion of our	Providing an uninterrupted
Hospital business	supply of our products

Advancing high-impact	Achieving cost savings and
R&D and regulatory	helping reduce economic
initiatives	pressures through the
	Operational Excellence
	Program

33

FY'23 - FY'26: Transformational Growth

CORPORATE STRATEGY

Compete in winning

segments and geographies

Achieve leading positions

Deliver superior

operating performance

4

GOALS

GROWTH

Revenue

Profitability

Cash Flow

	DIVERSIFICATION		SUSTAINABILITY
•	Business Segments	•	Economic
•	Customers	•	People
•	Geographies	•	Societal
•	Business Models	•	Environmental

Robust Shareholder Value Creation Model

SUSTAINABLE

GROWTH

HIGH

SINGLE DIGIT

organic revenue CAGR

MID TEENS

CAGR in adjusted diluted EPS

INCREASING

PROFITABILITY

HIGH TEENS

CAGR in adjusted operating income

HIGH TWENTIES

adjusted operating income

margin in FY'26

CAPITAL

ALLOCATION

$0.6B TO $0.7B

of cumulative FCF1 FY'23 - FY'26

UP TO $2.1B

in capital capacity2 to support a disciplined capital allocation strategy

1. Free cash flow after restructuring and restructuring-related costs. 2) Capital capacity by the end of FY'26.

5